Europe Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology and Others) Population (Adults, Pediatric and Geriatric), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Europe Iron-Deficiency Anemia Therapy Market Analysis and Size
Anemia is one of the most prevalent blood disorders in the current times. Intravenous iron drugs are facing much use due to its improved quality of treatment outside the dialysis, rising the number of dialysis patients, increasing number of diabetic patients globally and increasing aging population. R&D in the treatment of iron deficiency anemia will create a competitive advantage for several manufacturers with new and innovative therapies in effective ways to develop and assess iron deficiency anemia therapy.
Data Bridge Market Research analyses a growth rate in the Europe iron-deficiency anemia therapy market in the forecast period 2023-2030. The expected CAGR of Europe iron-deficiency anemia therapy market is tend to be around 16.5% in the mentioned forecast period. The market was valued at USD 1085.6 million in 2022, and it would grow upto USD 3683.6 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Iron-Deficiency Anemia Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology and Others) Population (Adults, Pediatric and Geriatric), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), Covis Pharma GmbH (U.S.), PHARMACOSMOS A/S (Denmark), Vifor Pharma Management Ltd. (Switzerland), Orion Corporation (Finland), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India)
|
|
Market Opportunities
|
|
Market Definition
Iron deficiency anemia is a type of anemia that occurs when the body's iron stores are reduced. Anemia is specified by an inadequacy of healthy red blood cells. RBCs supply oxygen to human tissues. Iron is important in the production of haemoglobin. Haemoglobin deficiency shows lack of oxygen in the body. It's essential to keep your iron levels in check. Consumption of iron-rich foods such as meat, vegetables, fruits, and cereals can help to treat or prevent iron deficiency. Vitamin C can help to prevent iron deficiency.
Europe Iron-Deficiency Anemia Therapy Market Dynamics
Drivers
- Rising Incidences of Chronic Kidney Disease
According to the records of National Kidney Foundation, Inc., the two primary causes of chronic kidney disease are diabetes and hypertension. Data shows that about 10% of the European population is affected by chronic kidney disease, with more than 2 million individuals getting dialysis on a regular basis. Large number of individuals who are suffering from this disease are not aware until serious symptoms appear. It is anticipated that chronic kidney cases will rise across highly economic countries, such as India and China that infers an increase in the aged population over the upcoming years.
- Growing Adoption of Oral Iron Therapy
The oral iron therapy is anticipated to witness huge growth during the forecast period due to the factors such as rise in the patient population suffering from anemia and anemia-causing diseases. In addition to this, increasing number of research that supports the use of oral iron therapy as a substitute to intravenous treatments in hospital settings is also anticipated to increase the adoption of oral iron therapy among people, thus boosting the segment growth
Opportunities
- Increase in Anaemia
According to the records of the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anaemia in Europe. Rising incidence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, liver disorders, thyroid diseases, cancer, and inflammatory bowel diseases, is a primary factor helping in the growth of the market for intravenous iron. According to the records of WHO, about 42% of children below the age of 5 years and 40% of pregnant women suffer from some form of anaemia. Therefore, it creates opportunity for the market growth.
- Increasing Incidence of Cancer
A rising number of cancer patients tend to develop iron deficiency anemia. Common types of cancer that are widely associated with anemia includes bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer. Lung and breast tumors have been specified with the highest prevalence of anemia among solid tumors. Hematologic malignancies such as lymphoma, leukemia, and multiple myeloma produce abnormal blood cells that as a result harm the immune system and cause anemia. Cancer treatments such as chemotherapy and radiation therapy also increase anemia in cancer patients. This creates more opportunities in the market.
Restraints/Challenges
- Stringent Regulations by Different Associations
Numerous strict regulations are related with the intravenous iron drugs. Various government associations, such as FDA and European Medicines Agency have imposed stringent regulations for intravenous iron drugs approval and usage which takes longer to get approved and launched. Therefore, it hampers the market growth.
- Serious Effects of Iron Supplements
There are few adverse effects that are related with the intake of iron drugs. Common effects of include digestive problems such as loss of appetite, constipation, nausea, stomach aches, and vomiting. The overdose of these drugs may also lead to tiredness or weakness, shallow or rapid breathing, convulsions, fatigue, bluish skin, pale skin or fingernails. Thus, this hampers the market growth.
This Europe iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Europe Iron-Deficiency Anemia Therapy Market
The COVID-19 outbreak has disturbed the manufacturing and supply of intravenous iron drugs, however, increased initiatives by manufacturers and government to meet the demand has aided the growth of the market for intravenous iron drugs. In addition to this, numerous studies have recommended that Covid-19 infection has a huge risk of Acute Kidney Injury (AKI) and CKD, which, in turn, has fuelled the demand for intravenous iron drugs to treat CKD-related anemia. Health authorities advised that COVID-19 patients with an acute kidney injury should be tested often as their risk of developing CKD is higher than others. Thus, COVID-19 had a major impact on the market growth.
Europe Iron-Deficiency Anemia Therapy Market Scope
The Europe iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Parenteral Iron Therapy
- Oral Iron Therapy
Therapy Areas
- Inflammatory Bowel Disease
- Renal
- Obstetrics and Gynecology
- Congestive Heart Failure (CHF)
- Oncology
- Others
Population
- Adults
- Pediatric
- Geriatric
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights
The Europe iron-deficiency anemia therapy market is analyzed and market size insights and trends are provided by therapy, therapy areas, population, distribution channel and end-user as referenced above.
The major countries covered in the europe iron-deficiency anemia therapy market report are the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany is leading the market because of the quality and management of health care system, growing research and development activities of anemia drugs among scientists. Also, increased awareness, growing investment by government firm and presence of generic players is leading the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Iron-Deficiency Anemia Therapy Market Share Analysis
The Europe iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe iron-deficiency anemia therapy market.
Key players operating in the Europe iron-deficiency anemia therapy market include:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Covis Pharma GmbH (U.S.)
- PHARMACOSMOS A/S (Denmark)
- Vifor Pharma Management Ltd. (Switzerland)
- Orion Corporation (Finland)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
SKU-